Fecal Microbiota Transplantation in the Treatment Strategy of Inflammatory Bowel Disease: Molecular Mechanisms, Clinical Evidence, and the Transition Toward Defined Microbial Therapeutics
- 1Department of Medical Microbiology, Medical School, University of Pécs, 7623 Pécs, Hungary
- 21st Department of Internal Medicine, Medical School, University of Pécs, 7623 Pécs, Hungary
- 3Department of Infectology, Somogy County Kaposi Mór Teaching Hospital, 7400 Kaposvár, Hungary
Abstract
Inflammatory Bowel Disease (IBD) comprises two clinically and pathologically distinct chronic intestinal inflammatory diseases, ulcerative colitis (UC) and Crohn’s disease (CD). Both diseases result from a dysregulated mucosal immune response to the commensal gut microbiota in genetically predisposed individuals. Because gut dysbiosis is a constant feature of both diseases, Fecal Microbiota Transplantation (FMT) has recently been investigated as a potential therapeutic strategy to restore a balanced microbiota composition in patients with IBD. There are five placebo-controlled randomized controlled trials (RCTs) in UC and several meta-analyses, which showed that treatment with FMT using material from multiple donors can lead to clinical and endoscopic remission in patients with mild-to-moderate UC and may thus double to triple the rate of remission compared with placebo (number needed to treat [NNT] ≈ 3–5). In contrast, evidence for CD is limited and inconsistent, with one promising pilot study being contrasted with a large multicenter induction trial that was stopped for futility. This review provides an update of the current molecular understanding of FMT-induced recovery of mucosal barrier function and inflammation control in intestinal inflammation (α-diversity restoration and subsequent donor strain engraftment, production of short-chain fatty acids and secondary bile acids, tryptophan–AhR signaling, IL-10-mediated induction of Tregs vs. suppression of Th17 cells and restoration of epithelial barrier function). The review also summarizes the current clinical evidence for the use of FMT in IBD, its safety, and the current regulatory status. It also describes recent developments in FMT, including the use of defined bacterial consortia, ‘live biotherapeutic products’ (LBPs), and donor–recipient pairing. Collectively, FMT provides evidence of principle for manipulating intestinal microbial ecosystems to treat immune-mediated intestinal inflammation.
Related
- Adolescent depression and gut microbiota dysbiosis: characteristics, mechanisms, and microbiota-targeted therapeutics.
- Deciphering the Immune–Bone Interaction Network in Diabetic Bone Fragility: Inflammatory Mechanisms and Precision Therapeutics
- Effects of Fecal Microbiota Transplantation on Inflammatory Markers in Parkinson’s Disease: Exploratory Results from the EFFACE-PD Study
- Gut Microbiota Dysbiosis in Advanced Chronic Kidney Disease and Kidney Transplantation: A Narrative Review of Pathophysiological Mechanisms, Implications for Nutritional Status, and Biotic Interventions
- Gut microbiota–mediated tryptophan metabolic dysregulation in the comorbidity of inflammatory bowel disease and autism spectrum disorder: mechanisms and research progress
BibTeX
@article{peto2026fecal,
title = {{Fecal Microbiota Transplantation in the Treatment Strategy of Inflammatory Bowel Disease: Molecular Mechanisms, Clinical Evidence, and the Transition Toward Defined Microbial Therapeutics}},
author = {Anna Pető and David Sipos and Ágnes Kappéter and Zsofia Feiszt and Fanni Dembrovszky and Bernadett Halda-Kiss and Zoltán Péterfi},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272110001},
url = {https://www.mdpi.com/1422-0067/27/21/10001},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Fecal Microbiota Transplantation in the Treatment Strategy of Inflammatory Bowel Disease: Molecular Mechanisms, Clinical Evidence, and the Transition Toward Defined Microbial Therapeutics
AU - Anna Pető
AU - David Sipos
AU - Ágnes Kappéter
AU - Zsofia Feiszt
AU - Fanni Dembrovszky
AU - Bernadett Halda-Kiss
AU - Zoltán Péterfi
PY - 2026
DA - 2026/11/08
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272110001
UR - https://www.mdpi.com/1422-0067/27/21/10001
AB - Inflammatory Bowel Disease (IBD) comprises two clinically and pathologically distinct chronic intestinal inflammatory diseases, ulcerative colitis (UC) and Crohn’s disease (CD). Both diseases result from a dysregulated mucosal immune response to the commensal gut microbiota in genetically predisposed individuals. Because gut dysbiosis is a constant feature of both diseases, Fecal Microbiota Transplantation (FMT) has recently been investigated as a potential therapeutic strategy to restore a balanced microbiota composition in patients with IBD. There are five placebo-controlled randomized controlled trials (RCTs) in UC and several meta-analyses, which showed that treatment with FMT using material from multiple donors can lead to clinical and endoscopic remission in patients with mild-to-moderate UC and may thus double to triple the rate of remission compared with placebo (number needed to treat [NNT] ≈ 3–5). In contrast, evidence for CD is limited and inconsistent, with one promising pilot study being contrasted with a large multicenter induction trial that was stopped for futility. This review provides an update of the current molecular understanding of FMT-induced recovery of mucosal barrier function and inflammation control in intestinal inflammation (α-diversity restoration and subsequent donor strain engraftment, production of short-chain fatty acids and secondary bile acids, tryptophan–AhR signaling, IL-10-mediated induction of Tregs vs. suppression of Th17 cells and restoration of epithelial barrier function). The review also summarizes the current clinical evidence for the use of FMT in IBD, its safety, and the current regulatory status. It also describes recent developments in FMT, including the use of defined bacterial consortia, ‘live biotherapeutic products’ (LBPs), and donor–recipient pairing. Collectively, FMT provides evidence of principle for manipulating intestinal microbial ecosystems to treat immune-mediated intestinal inflammation.
SN - 1422-0067
ER -